Detalles de la búsqueda
1.
Long-Acting Cabotegravir and Rilpivirine Dosed Every 2 Months in Adults With Human Immunodeficiency Virus 1 Type 1 Infection: 152-Week Results From ATLAS-2M, a Randomized, Open-Label, Phase 3b, Noninferiority Study.
Clin Infect Dis
; 76(9): 1646-1654, 2023 05 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-36660819
2.
Expanded Multivariable Models to Assist Patient Selection for Long-Acting Cabotegravir + Rilpivirine Treatment: Clinical Utility of a Combination of Patient, Drug Concentration, and Viral Factors Associated With Virologic Failure.
Clin Infect Dis
; 77(10): 1423-1431, 2023 11 17.
Artículo
en Inglés
| MEDLINE | ID: mdl-37340869
3.
Compassionate use of long-acting cabotegravir plus rilpivirine for people living with HIV-1 in need of parenteral antiretroviral therapy.
HIV Med
; 24(2): 202-211, 2023 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-35945163
4.
Phase 2 Open-Label Study of Long-Term Safety, Tolerability, and Antiviral Activity of Rilpivirine in Antiretroviral-Naive Adolescents Living with HIV-1.
Antimicrob Agents Chemother
; 66(2): e0091621, 2022 02 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-34871089
5.
Impact of Integrase Sequences from HIV-1 Subtypes A6/A1 on the In Vitro Potency of Cabotegravir or Rilpivirine.
Antimicrob Agents Chemother
; 66(3): e0170221, 2022 03 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-34978890
6.
Long-acting cabotegravir and rilpivirine dosed every 2 months in adults with HIV-1 infection (ATLAS-2M), 48-week results: a randomised, multicentre, open-label, phase 3b, non-inferiority study.
Lancet
; 396(10267): 1994-2005, 2021 12 19.
Artículo
en Inglés
| MEDLINE | ID: mdl-33308425
7.
Observational cohort study of rilpivirine (RPV) utilization in Europe.
AIDS Res Ther
; 19(1): 38, 2022 08 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-35933352
8.
Pharmacokinetic Interactions between Simeprevir and Ledipasvir in Treatment-Naive Hepatitis C Virus Genotype 1-Infected Patients without Cirrhosis Treated with a Simeprevir-Sofosbuvir-Ledipasvir Regimen.
Antimicrob Agents Chemother
; 61(12)2017 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-28971875
9.
Deep sequencing analysis of HIV-1 reverse transcriptase at baseline and time of failure in patients receiving rilpivirine in the phase III studies ECHO and THRIVE.
J Med Virol
; 88(5): 798-806, 2016 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-26412111
10.
Evolution of hepatitis C virus quasispecies during repeated treatment with the NS3/4A protease inhibitor telaprevir.
Antimicrob Agents Chemother
; 59(5): 2746-55, 2015 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-25712364
11.
Efficacy, safety, and tolerability of switching to long-acting cabotegravir plus rilpivirine versus continuing fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide in virologically suppressed adults with HIV, 12-month results (SOLAR): a randomised, open-label, phase 3b, non-inferiority trial.
Lancet HIV
; 10(9): e566-e577, 2023 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-37567205
12.
Comparison of phenotypic and genotypic tropism determination in triple-class-experienced HIV patients eligible for maraviroc treatment.
J Antimicrob Chemother
; 66(2): 265-72, 2011 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-21196489
13.
Long-term safety and efficacy of rilpivirine in combination with nucleoside/nucleotide reverse transcriptase inhibitors in HIV-1 infected patients: 336-week rollover study of phase 2b and 3 clinical studies.
Antivir Ther
; 26(6-8): 95-105, 2021 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-35485339
14.
Exploring predictors of HIV-1 virologic failure to long-acting cabotegravir and rilpivirine: a multivariable analysis.
AIDS
; 35(9): 1333-1342, 2021 07 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-33730748
15.
Long-acting cabotegravir and rilpivirine dosed every 2 months in adults with HIV-1 infection (ATLAS-2M), 96-week results: a randomised, multicentre, open-label, phase 3b, non-inferiority study.
Lancet HIV
; 8(11): e679-e689, 2021 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-34648734
16.
Long-acting cabotegravir plus rilpivirine for treatment in adults with HIV-1 infection: 96-week results of the randomised, open-label, phase 3 FLAIR study.
Lancet HIV
; 8(4): e185-e196, 2021 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-33794181
17.
Secondary integrase resistance mutations found in HIV-1 minority quasispecies in integrase therapy-naive patients have little or no effect on susceptibility to integrase inhibitors.
Antimicrob Agents Chemother
; 54(9): 3938-48, 2010 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-20479206
18.
HIV-1 V3 envelope deep sequencing for clinical plasma specimens failing in phenotypic tropism assays.
AIDS Res Ther
; 7: 4, 2010 Feb 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-20804564
19.
Long-Acting Injectable Cabotegravir + Rilpivirine for HIV Maintenance Therapy: Week 48 Pooled Analysis of Phase 3 ATLAS and FLAIR Trials.
J Acquir Immune Defic Syndr
; 85(4): 498-506, 2020 12 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-33136751
20.
Susceptibility of human immunodeficiency virus type 1 to the maturation inhibitor bevirimat is modulated by baseline polymorphisms in Gag spacer peptide 1.
Antimicrob Agents Chemother
; 53(5): 2185-8, 2009 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-19223634